|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Olanzapine dosage** | | **No. of studies** | **No. of patients** | **Mode** | **RR and 95%CI** | **Heterogeneity** | | **P value for two groups** |
| ***P*** | ***I2* (%)** |
| Acute CINV | 10mg | 6 | 321/308 | Fixed | 0.65 (0.45; 0.95) | 0.95 | 0.0 | 0.53 |
| 5mg | 4 | 181/180 | Fixed | 0.56( 0.43; 0.74) | 0.45 | 0.0 |
| Delayed CINV | 10mg | 6 | 321/308 | Random | 0.37(0.20; 0.69) | 0.00 | 78.3 | 0.13 |
| 5mg | 5 | 240/238 | Fixed | 0.58( 0.48; 0.70) | 0.47 | 0.0 |

Table 3. The results of subgroup analysis about olanzapine dosage (10mg vs. 5mg)